Related Experiment Video

Updated: Oct 3, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

Statins prevent endothelial cell activation induced by antiphospholipid (anti-beta2-glycoprotein I) antibodies:

P L Meroni1, E Raschi, C Testoni

  • 1IRCCS Istituto Auxologico Italiano, Milan, Italy. pierluigi.meroni@unimi.it

Arthritis and Rheumatism
|January 5, 2002
PubMed

Insights

Statins, like fluvastatin, can inhibit endothelial cell activation caused by anti-beta2-glycoprotein I antibodies. This finding suggests statins may be a valuable treatment for antiphospholipid syndrome (APS).

Area of Science:

  • Immunology
  • Cardiovascular Research
  • Pharmacology

Background:

  • Endothelial cell activation plays a role in the pathogenesis of antiphospholipid syndrome (APS).
  • Anti-beta2-glycoprotein I (anti-beta2GPI) antibodies are implicated in triggering endothelial cell activation.
  • Statins are known inhibitors of HMG-CoA reductase.

Purpose of the Study:

  • To investigate the in vitro effect of statins on endothelial cell activation induced by anti-beta2GPI antibodies.
  • To explore the potential of statins as a therapeutic strategy for APS.

Main Methods:

  • Human umbilical vein endothelial cells (HUVECs) were assessed for activation markers including U937 monocyte adhesion, E-selectin, and ICAM-1 expression.
  • Interleukin-6 (IL-6) mRNA expression and NF-kappaB DNA-binding activity were analyzed.
  • HUVECs were stimulated with anti-beta2GPI antibodies, cytokines (IL-1beta, TNF-alpha), or LPS.

Main Results:

  • Fluvastatin significantly reduced U937 monocyte adhesion and E-selectin/ICAM-1 expression induced by anti-beta2GPI antibodies, cytokines, and LPS in a concentration-dependent manner.
  • Simvastatin showed similar but less potent inhibitory effects.
  • Fluvastatin's inhibition of E-selectin expression correlated with impaired NF-kappaB DNA binding and reduced IL-6 mRNA levels; mevalonate partially reversed these effects.

Conclusions:

  • Statins effectively inhibit endothelial cell activation mediated by anti-beta2GPI antibodies in vitro.
  • These findings provide a scientific basis for considering statins as an adjunctive therapy in managing antiphospholipid syndrome (APS).
  • Statins represent a potential therapeutic avenue for APS by targeting endothelial dysfunction.
Abstract

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Inflammation01:38

Inflammation

Overview
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...